TY - JOUR T1 - Exploring the neutrophil/lymphocyte and platelet/lymphocyte ratios as biomarkers for lung cancer development JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA4241 VL - 46 IS - suppl 59 SP - PA4241 AU - Pablo Sanchez-Salcedo AU - Jessica Gonzalez AU - Diego Martinez-Urbistondo AU - Juan Berto AU - Pilar Rivera AU - Esmeralda Lopez-Zalduendo AU - Ana Belen Alcaide AU - Arantzazu Campo AU - Juan Pablo De Torres AU - Javier Zulueta Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA4241.abstract N2 - Elevated neutrophil/lymphocyte (NLR) and platelet/lymphocyte ratios (PLR) have been recognized as poor prognostic indicators at time of cancer diagnosis. There is no data on whether a progressive increase of these ratios can be early indicators of cancer development.We analyzed the lung cancer (LC) cases detected in the Pamplona Lung Cancer Screening Program between 2001 and 2015. Complete blood counts (CBC) were registered at annual intervals between enrolment and time of diagnosis. Linear regression analysis was used to calculate the mean annual change in NLR and PLR in those with at least 3 CBCs. Results were compared to a matched group of participants who didn't develop LC.Thirty-two out of 55 LC had at least 3 CBCs before diagnosis. At enrolment, NLR and PLR were similar between subjects who developed LC (n=32) and controls (n=103) (Table 1). After a median follow-up of 80 months and a median of 4 (IQR 3-6) CBCs, subjects who developed LC showed faster NLR and PLR annual progressions (2.56% vs. 0.27% [p=0.4] per year; and 3.75% vs. 0.33% [p=0.02] per year, respectively) (Table 2). Annual NLR and PLR change was associated to a 3% (HR 1.03; CI95% 0.98-1.1, p=0.2) and 5% increase in LC risk (HR 1.05; CI95% 1.0-1.1, p=0.04), respectively.In a LC screening setting, a progressive increase in PLR could suggest lung cancer development. Larger studies are needed to confirm this observation. ER -